Is Monobenzone FDA-Approved in 2026?
Short answer. Yes — the active ingredient monobenzone remains an FDA-approved drug for the treatment of extensive vitiligo. The Valeant brand “Benoquin” was discontinued in the United States around 2008 for commercial reasons, but the FDA’s approval of the drug itself was never withdrawn. US patients today access monobenzone through US compounding pharmacies or via personal importation from international manufacturers, both under existing FDA regulatory frameworks.
The “is monobenzone FDA-approved?” question generates persistent confusion because of the gap between brand-name approval and active-ingredient approval. The two are different and the distinction matters. This article walks through the regulatory facts as they stand in mid-2026.
The two questions that get conflated
When patients ask “is monobenzone FDA-approved?”, they’re usually asking one of two different questions:
Is the active ingredient (the drug molecule) approved by the FDA for clinical use? → Yes.
Is there a currently-marketed FDA-approved brand-name monobenzone product in the United States? → No, since around 2008.
Both answers are correct simultaneously. The active ingredient retains FDA approval; the original brand-name product no longer exists in the US market. US patients today obtain monobenzone through US compounding pharmacies (which use the FDA-approved active ingredient under FDA’s compounding regulations) or via personal importation of international-manufactured monobenzone (under FDA’s personal-importation policy).
The FDA approval history of monobenzone
Monobenzone was first approved by the FDA in the 1960s for the treatment of extensive vitiligo. The approval mechanism was the standard New Drug Application (NDA) pathway that exists for prescription medications.
The brand-name product Benoquin was developed and marketed by Neutrogena Corporation, was subsequently owned by ICN Pharmaceuticals, and was inherited by Valeant Pharmaceuticals International when Valeant acquired ICN’s portfolio in 2003.
The FDA-approved indication has been consistent across decades:
“Final depigmentation in extensive vitiligo”
with the typical clinical interpretation that “extensive” means more than 50% of body surface area. Subsequent dermatology guidance has refined the interpretation but not changed the underlying approval.
What happened in 2008
Around 2008, Valeant Pharmaceuticals voluntarily discontinued the Benoquin brand in the United States. The discontinuation was a commercial decision, not an FDA enforcement action or safety withdrawal:
- The depigmentation-therapy market is small and specialised
- The medication is used for ~12 months by patients, then taper to twice-weekly maintenance — no large chronic-use base
- Valeant’s portfolio strategy at the time prioritised higher-volume products
The key point about the discontinuation: the FDA did not withdraw the drug’s approval. The approval remained on the books. Valeant simply stopped manufacturing under the Benoquin label.
This pattern — small-market drugs being commercially discontinued while their FDA approval remains technically in force — is not unique to monobenzone. It happens across rare-disease and small-market pharmaceutical categories.
For the full discontinuation story and its implications for patients, see Benoquin Cream Discontinued in the US — Why It Happened.
How US patients access monobenzone today (within FDA frameworks)
Two pathways, both legal:
1. US compounding pharmacies (FDA 503A)
Specialty compounding pharmacies in the US — including CareFirst Specialty Pharmacy, CFS, Nigehban, and others — produce monobenzone on prescription for individual patients. The framework is FDA 503A pharmacy compounding, a long-established legal pathway for pharmacies to prepare a medication on prescription for a specific patient.
The compounding pharmacies use FDA-recognised monobenzone USP as the active ingredient. The formulation (cream base) is prepared by the compounding pharmacist. The dispensed product is, pharmacologically, equivalent to the original Valeant Benoquin.
Cost: typically $80 to $200 per 30 g tube. Insurance coverage is rare for depigmentation indications.
2. Personal importation (FDA Personal Importation Policy)
The FDA operates a personal-importation policy that explicitly accommodates patients importing a personal supply of an unapproved drug for a serious condition, with a prescription, in reasonable quantity.
Key criteria the policy references:
- The drug is for treatment of a serious condition
- The drug is not commercially promoted to US persons
- The drug does not represent an unreasonable risk
- The patient affirms in writing that it is for personal use
- The supply is generally not more than ~90 days
- A US-licensed physician is responsible for the patient’s treatment
Monobenzone for diagnosed extensive vitiligo meets these criteria. US patients commonly import from WHO-GMP-certified Indian manufacturers (Puneet Labs, Unique Pharma, EL.V. Life Sciences and others) on this basis.
For the practical mechanics, see FDA Personal Importation Guide for Monobenzone.
What “FDA-approved” means in different contexts
Some clarifying language because patients (reasonably) get confused:
- “FDA-approved active ingredient” — the drug molecule has been reviewed by FDA and approved for at least one clinical indication. Monobenzone qualifies.
- “FDA-approved brand-name product” — a specific manufacturer’s specific formulation has been approved by FDA and is currently marketed. No currently-marketed FDA-approved monobenzone brand product exists in the US.
- “FDA-approved for a specific indication” — the drug has been formally approved for a specific medical use. Monobenzone is FDA-approved for “final depigmentation in extensive vitiligo.”
- “FDA-cleared” — a slightly different category, used for medical devices. Not applicable to monobenzone.
When a US dermatologist says “monobenzone is FDA-approved,” they almost always mean “the active ingredient is FDA-approved for vitiligo depigmentation.” That is correct.
When a pharmacist says “there is no FDA-approved monobenzone product available,” they mean “no currently-marketed brand-name product exists.” That is also correct.
Both statements are simultaneously true.
What about the 40% concentration?
The original Benoquin product was 20% monobenzone. That was the FDA-approved concentration.
The 40% strength (sold internationally as Uniqueen Plus / Benoquin 40%) is off-label — there is no FDA-approved 40% monobenzone product. Compounding pharmacies can produce 40% on prescription; international manufacturers (primarily Unique Pharma in India) sell it commercially. Off-label use of medications is a long-established and legal medical practice in the United States; dermatologists prescribe off-label all the time.
The “off-label” designation means:
- The FDA has not specifically approved the 40% concentration for the indication
- Insurance coverage is even less likely than for 20%
- The prescribing physician takes on responsibility for the clinical judgment to prescribe at that strength
- The medication itself is identical to 20% — just at twice the concentration
For the strength comparison, see Monobenzone 20% vs 40%.
Could FDA approval change?
Three scenarios worth considering:
1. A new manufacturer launches a branded monobenzone product. Possible but unlikely on commercial grounds. The market is small; the development costs are high; no major manufacturer has signaled interest. If it happened, it would be a return to the pre-2008 situation — a brand-name product back on US shelves alongside the active ingredient remaining approved.
2. FDA withdraws the approval entirely. Would require new safety evidence or a regulatory action. There’s no current signal this is being considered. Recent research raising questions about systemic oxidative-stress effects has not (yet) prompted any regulatory review.
3. The framework around personal importation tightens. Possible. The personal-importation policy is FDA guidance, not statute, and FDA could narrow it. There are no current signals of this for monobenzone specifically, but it’s a watch-this-space concern over multi-year horizons.
For now, the regulatory status is stable: active ingredient approved, no brand-name product, two legal access pathways (compounding and personal importation).
What this means for patients
If you’re considering monobenzone treatment and someone tells you it’s “not FDA-approved,” that’s incomplete information. The accurate framing:
- The drug is FDA-approved for extensive vitiligo
- The original brand product was discontinued for commercial reasons
- Two legal access pathways exist
- Your dermatologist can prescribe and the supply chain is established
If someone tells you it’s “totally FDA-approved with no caveats,” that’s also incomplete. The accurate framing includes the brand discontinuation, the absence of a currently-marketed FDA-approved formulation, and the dependence on either compounding or personal importation for supply.
The honest, complete picture is what helps you make informed decisions about treatment.
Frequently asked questions
Is monobenzone illegal to import? No, under personal-importation rules with appropriate documentation. See FDA Personal Importation Guide.
Will my dermatologist write a prescription for an unapproved drug? Monobenzone is not unapproved — the active ingredient is FDA-approved. US dermatologists routinely write prescriptions for monobenzone, fulfilled either by US compounding pharmacies or for personal importation.
What about the FDA warnings on hydroquinone? Those are about hydroquinone, a different (related but separate) drug. The 2020 FDA action removed 2% OTC hydroquinone products from the US market over safety concerns. That action does not apply to monobenzone, which is a different molecule with a different regulatory history. See Monobenzone vs Hydroquinone.
Has the FDA ever recalled monobenzone? No. The 2008 discontinuation by Valeant was a voluntary commercial decision, not a recall. There is no FDA recall record for monobenzone.
Will the FDA approve a new brand-name monobenzone product in the future? Possible but not currently planned by any manufacturer that has publicly disclosed plans. The economic case has not changed since 2008.
Order monobenzone with your prescription
EL.V. Life Sciences supplies monobenzone-based brands from a WHO-GMP plant in India against valid prescriptions, with documentation pack to support personal importation. Order with prescription → or WhatsApp us.
Related: Main monobenzone landing page · Benoquin discontinued in the US · FDA personal importation · Indian vs US-compounded monobenzone.
Sources
- FDA — Personal Importation Policy
- Drugs.com — Benoquin prescribing information
- SkinSafe — Benoquin Cream (Valeant/ICN)
- FDA Drug Approvals Database
Medically reviewed by Dr. [Name], MD Dermatology · Last updated 29 May 2026
You might also like
What Is Monobenzone Cream? A Complete Guide
What Is Monobenzone Cream? A Complete Guide Monobenzone is a prescription depigmenting medication used in the treatment of…
Read article →
Monobenzone for Vitiligo on the Face — What’s Different
Monobenzone for Vitiligo on the Face — What’s Different The face is the most visible and the most…
Read article →
Cost of Monobenzone Treatment for Vitiligo — Full 12-Month Budget
Cost of Monobenzone Treatment for Vitiligo — Full 12-Month Budget Cost ranges in this article are illustrative as…
Read article →